Biomarker validation for early–diagnosis of lupus nephritis using liquid biopsies
We are broadening the scope of our research by initiating a prospective study involving newly diagnosed Systemic Lupus Erythematosus (SLE) patients as well as those SLE patients without renal complications, spanning from 2023 to 2026 including patients from Oslo University hospital (OUS), Martina Hansens Hospital and University hospital of North (UNN). The primary outcome of this study is to validate the diagnostic accuracy, prognostic impact, and monitoring effectiveness of our biomarkers, thereby enhancing the overall diagnostic framework using blood and urine samples. In addition, we are collaborating with European LUpuS Inception-Cohort Developing initiATivE (ELUCIDIATE ) – the largest European SLE biobank. The biobank, in particular, will facilitate the analysis of a diverse array of biological specimens, deepening our insight into the pathophysiology of SLE and supporting the creation of increasingly precise biomarkers. We are committed to improving SLE patient care and advancing kidney health.